Michael Castagna

Chief Executive Officer
MannKind Corporation

Michael Castagna, PharmD, has been a transformative force since joining MannKind Corporation in 2016. He has helmed a resurgence at the company, bringing it from near bankruptcy to a robust financial position and propelling a burgeoning product pipeline.

Castagna oversaw the acquisition of QrumPharma in December 2020 to bolster MannKind's pipeline efforts to treat unmet needs for orphan lung diseases, an area where he envisioned leveraging MannKind's innovative technology to create differentiated therapeutic products. He orchestrated a worldwide licensing agreement with United Therapeutics in 2018 that has resulted in the development of Tyvaso DPI (trepostinil) inhalation powder that is currently pending FDA approval. With approval, Tyvaso DPI will become the first and only approved dry powder inhaler for use by patients living with the serious medical conditions of PAH and PH-ILD. Castagna also established an Endocrine Business Unit (EBU) at MannKind.